PMID- 8101380
OWN - NLM
STAT- MEDLINE
DCOM- 19930819
LR  - 20190712
IS  - 0091-3057 (Print)
IS  - 0091-3057 (Linking)
VI  - 45
IP  - 3
DP  - 1993 Jul
TI  - Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced 
      neurotoxicity.
PG  - 647-53
AB  - The effect of acute, reversible depletion of either serotonin 
      [5-hydroxytryptamine (5-HT)] or dopamine (DA) on the long-term (7-day) decrease 
      of brain 5-HT content produced after 3,4-methylenedioxymethamphetamine (MDMA) 
      administration was investigated. The tyrosine hydroxylase inhibitor 
      alpha-methyl-p-tyrosine (alpha-MPT) significantly attenuated the acute increase 
      in DA efflux produced by MDMA in the striatum as measured by in vivo 
      microdialysis. Treatment with alpha-MPT had no effect on MDMA-induced 5-HT 
      release. alpha-MPT treatment blocked the long-term (7-day) depletion of striatal 
      5-HT content after MDMA administration. The tryptophan hydroxylase inhibitor 
      p-chlorophenylalanine (PCPA) completely blocked the acute increase in the 
      extracellular concentration of 5-HT produced by MDMA. Although PCPA significantly 
      attenuated the increase in DA efflux produced by MDMA, the effect was small in 
      magnitude. More importantly, treatment with PCPA had no effect on MDMA-induced 
      decrease of 5-HT uptake sites in the frontal cortex. These data are suggestive 
      that acute depletion of DA but not 5-HT protects against the long-term neurotoxic 
      effects of MDMA on 5-HT axon terminals. In addition, these data are supportive of 
      the hypothesis that DA plays a major role in the neurotoxic effects of MDMA.
FAU - Brodkin, J
AU  - Brodkin J
AD  - Department of Psychiatry, School of Medicine, Case Western Reserve University, 
      Cleveland, OH 44106-5000.
FAU - Malyala, A
AU  - Malyala A
FAU - Nash, J F
AU  - Nash JF
LA  - eng
GR  - DA07427/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pharmacol Biochem Behav
JT  - Pharmacology, biochemistry, and behavior
JID - 0367050
RN  - 0 (Biogenic Monoamines)
RN  - 0 (Designer Drugs)
RN  - 0 (Methyltyrosines)
RN  - 0 (Receptors, Serotonin)
RN  - 333DO1RDJY (Serotonin)
RN  - 41VRH5220H (Paroxetine)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - 658-48-0 (alpha-Methyltyrosine)
RN  - EC 1.14.16.2 (Tyrosine 3-Monooxygenase)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - R5J7E3L9SP (Fenclonine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/*analogs & derivatives/toxicity
MH  - Animals
MH  - Axons/metabolism/physiology
MH  - Biogenic Monoamines/*physiology
MH  - Brain Chemistry/drug effects
MH  - Designer Drugs/*toxicity
MH  - Dialysis
MH  - Dopamine/physiology
MH  - Fenclonine/pharmacology
MH  - Male
MH  - Methyltyrosines/pharmacology
MH  - N-Methyl-3,4-methylenedioxyamphetamine
MH  - Nerve Endings/metabolism/physiology
MH  - Nervous System Diseases/*chemically induced/physiopathology
MH  - Paroxetine/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Serotonin/drug effects/metabolism
MH  - Serotonin/physiology
MH  - Stereotaxic Techniques
MH  - Tyrosine 3-Monooxygenase/antagonists & inhibitors
MH  - alpha-Methyltyrosine
EDAT- 1993/07/01 00:00
MHDA- 1993/07/01 00:01
CRDT- 1993/07/01 00:00
PHST- 1993/07/01 00:00 [pubmed]
PHST- 1993/07/01 00:01 [medline]
PHST- 1993/07/01 00:00 [entrez]
AID - 0091-3057(93)90520-4 [pii]
AID - 10.1016/0091-3057(93)90520-4 [doi]
PST - ppublish
SO  - Pharmacol Biochem Behav. 1993 Jul;45(3):647-53. doi: 
      10.1016/0091-3057(93)90520-4.